Purchase Order 75N91025P00026
Award Date
12/8/24
Potential Completion Date
12/7/25
Potential Value
$15K
Federal Agency
National Cancer Institute
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
NAICS Category
811310 - Commercial and Industrial Machinery and Equipment (except Automotive and Electronic) Repair and Maintenance
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Rockville, MD 20852, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price purchase order contract awarded by the National Cancer Institute (NCI), a civilian agency, to Illumina, Inc., a for-profit manufacturer of genomics sequencing and analysis solutions. The contract, valued at $15,388.08, is for the provision of sequencing systems, reagents, and services to support genomic research and diagnostics. Illumina has a history of providing similar products and services to various federal agencies, including the NIH, CDC, USDA, and VA, under...
This is a $16,198 firm fixed price purchase order awarded by the National Cancer Institute to Illumina, Inc. for a service agreement to provide their MiSeq next-generation sequencing instrument. The contract has no set-aside designation and runs through July 31, 2025. Illumina is a manufacturer of genomic sequencing and analysis instruments and has previously been awarded prime contracts and subcontracts by the National Institutes of Health (NIH), Centers for Disease Control and Prevention...
This is a $263,862.50 firm fixed price purchase order awarded by the National Cancer Institute (NCI), a civilian agency under the National Institutes of Health (NIH), to Illumina, Inc. The contract is for the procurement of laboratory equipment and supplies, specifically various Illumina sequencing systems, reagents, and consumables to support the NCI Surgery Branch's genetic sequencing needs. The award does not have a set-aside designation. Illumina has previously received other prime federal...
This is a firm fixed price purchase order awarded by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc. for a service agreement to support the Illumina MiSeq sequencer. The award has a ceiling value of $20,009.24 and a completion date of December 7, 2024. Illumina is a manufacturer of sequencing and genomic analysis instruments and reagents that has previously received prime federal contracts and subcontracts to support...
This is a $17,508.94 firm fixed price delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency of the U.S. government, to Illumina, Inc., a for-profit manufacturer of sequencing and genomic analysis instruments and reagents. The contract is not set aside for any special designation. Illumina has previously been awarded prime federal contracts and subcontracts by agencies like the NIH, CDC, USDA, and VA to provide a range of sequencing systems, consumables, and...
This is a $28,749.60 firm-fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to Illumina, Inc., a manufacturer of sequencing and array-based genomic analysis solutions. The contract is for the provision of laboratory equipment and supplies, with no set-aside designation. Through this award, Illumina will provide the NCI with a range of its NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, as well as accompanying reagents, consumables, sample prep kits,...
This $95,931.00 firm fixed price purchase order was awarded by the National Institute of Environmental Health Sciences (NIEHS), a civilian federal agency, to Illumina, Inc., a for-profit manufacturer of genomic sequencing instruments and related products. The contract is for the provision of a MiSeq System, a genetic analysis platform used in life science research, applied markets, and molecular diagnostics. Illumina has a history of providing sequencing systems and consumables to support...
This is a firm fixed-price delivery order awarded by the National Cancer Institute, a civilian agency under the Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis products. The $24,230.96 contract provides Illumina sequencing systems, reagents, and services to support genomic research and diagnostics. The award is not associated with a set-aside program. Through past prime contract and subcontract awards, Illumina has...
This is a firm fixed-price Delivery Order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The $38,027.60 award is for the provision of lab supplies, specifically Illumina's NextSeq, NovaSeq, MiSeq, and iSeq sequencing systems, reagents, and consumables. This Delivery Order is likely part of a larger Indefinite...
This is a firm fixed price purchase order awarded by the National Cancer Institute, a civilian agency within the U.S. Department of Health and Human Services, to Illumina, Inc., a for-profit manufacturer of genomic sequencing and analysis equipment. The contract provides for an equipment maintenance agreement on Illumina sequencing systems, such as NextSeq, NovaSeq, MiSeq, and iSeq models, with a ceiling value of $16,198.00 and a performance period ending on December 4, 2025. The contract does...